CD274 and hepatocellular carcinoma: Currently, this combination has been approved for the treatment of advanced renal cell carcinoma (RCC), metastatic colorectal cancer with MMR/MSI-H aberrations, PD-L1-positive (≥1%) metastatic NSCLC, and HCC as well.